

**EIGHTH EDITION**

---

# **GREENFIELD'S NEUROPATHOLOGY**

---

## **VOLUME 1**

---

**GENERAL PATHOLOGY OF THE  
CENTRAL NERVOUS SYSTEM**

**HYPOXIA AND RELATED  
CONDITIONS**

**VASCULAR DISEASES**

**DISORDERS OF THE PERINATAL  
PERIOD**

**MALFORMATIONS**

**METABOLIC AND  
NEURODEGENERATIVE DISEASES  
OF CHILDHOOD**

**LYSOSOMAL DISEASES**

**MITOCHONDRIAL DISEASES**

**PEROXISOMAL DISEASES**

**NUTRITIONAL, METABOLIC AND  
TOXIC DISEASES**

**TRAUMA**

**EPILEPSY**

**DISEASES OF MOVEMENT AND  
SYSTEM DEGENERATIONS**

**AGEING AND DEMENTIA**

**PSYCHIATRIC DISEASES**

---

**EDITED BY**

**SETH LOVE, DAVID N LOUIS AND DAVID W ELLISON**

# Contents

Contributors	xxiii
Preface	xxvii
Abbreviations	xxix

## Volume 1

### Chapter 1: General pathology of the central nervous system

---

*Harry V Vinters and BK Kleinschmidt-DeMasters*

Neurons	1
Astrocytes	8
Role of astrocytes in central nervous system development and regeneration	14
Trophic effects and influence of astrocytes on vascular structure, integrity and physiology	17
Physiology, metabolism and neurochemistry of astrocytes	18
Pathological reactions and role in neurological disease	20
Oligodendrocytes	22
Ependyma	26
Microglia and macrophages	29
Identifying microglia and quantifying microgliosis	30
Microglial types	30
Functions of microglia	30
Pathological reactions of microglia	32
Microglia in disease/injury states	32
Distinguishing pathological abnormalities from artefacts and incidentals	34
Stem cells in the central nervous system: promise, potential and reality	34
Concept of the blood-brain barrier and the neurovascular unit	45
Determinants of intracranial pressure and pressure/volume relationships, and causes and consequences of raised intracranial pressure	47
Pathology of intracranial expanding lesions	47
Supratentorial expanding lesions	48
Supracallosal subfalcaline (or cingulate) hernia	48
Tentorial (uncal or lateral transtentorial) hernia	48
Central transtentorial herniation	50
Haemorrhage and infarction of the midbrain and pons	51
Tonsillar hernia (foraminal impaction, cerebellar cone)	51
Diffuse brain swelling	52

Infratentorial expanding lesions	52
External cerebral herniae	52
Hydrocephalus: pathophysiology, causes and consequences for the central nervous system	52
Treatment of hydrocephalus, and its effects on central nervous system structure and function	55
Acknowledgements	56
References	56

### Chapter 2: Hypoxia and related conditions

---

*Roland N Auer, Jeffrey F Dunn and Garnette R Sutherland*

Introduction	63
Oxygen delivery and metabolism	65
Ventilation	66
Circulation	67
Respiration	69
Selective neuronal necrosis versus pan-necrosis	71
Selective neuronal necrosis	71
Pan-necrosis or infarction	73
Acidophilic 'pink' neurons	74
Delayed neuronal death	76
Apoptosis	76
The hypoxic insults	76
Hypoxaemia	76
High-altitude hypoxia and brain damage	78
Severe hypoxia other than at altitude	78
Anaemia	79
Cardiac arrest encephalopathy (transient global ischaemia)	79
Hypoxia versus ischaemia	84
Ischaemic neuroprotection	87
Excitatory amino acid antagonism	88
Hyperoxic brain damage	89
Asphyxia	89
Histotoxic hypoxia	90
Air embolism and decompression sickness	91
Non-perfused brain (respirator brain; permanent global ischaemia)	92
'Swiss cheese brain'	94
Dark neurons	95
Clinical neuropathology	95
Experimental neuropathology	95
Carbon monoxide	96
Epidemiology	96

Carbon monoxide levels	96
Brain appearance in carbon monoxide poisoning	96
Mechanisms of brain damage in carbon monoxide poisoning	96
Low dose carbon monoxide exposure and psychic akinesia	98
White matter damage in carbon monoxide poisoning	99
Hypoglycaemic brain damage	99
History of hypoglycaemic brain damage	99
Biochemical basis of hypoglycaemic brain damage	100
Pharmacology of hypoglycaemic brain damage	101
Morphology of hypoglycaemic brain damage	101
Selective vulnerability	103
Selective vulnerability in general neuropathology	103
Selective vulnerability in hypoxic and ischaemic states	104
References	105

### Chapter 3: Vascular diseases

*Isidro Ferrer, Markku Kaste and Hannu Kalimo*

Introduction	121
Development and anatomy	121
Development of cerebral vasculature	121
Arterial blood supply	123
Venous drainage	127
Physiology of the cerebral circulation	131
Definitions and epidemiology of vascular disorders of the central nervous system	131
Stroke in general	131
Stroke incidence rates	132
Stroke mortality rates	133
Risk factors for stroke	133
Diseases affecting the blood vessels	134
Atherosclerosis	134
Diseases of small arteries	138
Small vessel disease	139
Cerebral amyloid angiopathy	142
Hereditary small vessel diseases	146
Inflammatory diseases	151
Vascular malformations and aneurysms	161
Miscellaneous diseases of blood vessels	173
Haematological disorders	176
Thrombosis and antithrombosis	176
Thrombophilia	177
Antiphospholipid antibodies	178
Polycythaemia and hyperviscosity	179
Anaemias	179
Platelet abnormalities	180
Consequences of cerebrovascular disorders	180
Focal cerebral arterial ischaemia	180
Venous thrombosis and infarction	203
Parenchymal brain haemorrhage	204
Subarachnoid haemorrhage	211
Vascular diseases of the spinal cord	214
Atherosclerosis of spinal cord arteries	214
Vascular malformations of the spinal cord	214
Spinal cord ischaemia	216

Vascular diseases of the pituitary gland	219
Acknowledgements	220
References	220

### Chapter 4: Disorders of the perinatal period

*Rebecca D Folkerth and Hannah C Kinney*

Introduction	241
Approach to evaluation of perinatal specimens	244
Brain growth	245
Cellular components of the developing human	
central nervous system	247
Neurons	247
Astrocytes	254
Oligodendrocytes and central nervous system myelination	256
Microglia	260
Ependyma	262
Cellular mechanisms of damage to the developing brain	263
Grey matter lesions	264
Hypoxic–ischaemic neuronal cell injury	264
Factors contributing to neuronal vulnerability to hypoxia–ischaemia in the perinatal brain	267
Neuropathology of neuronal injury in perinatal hypoxia–ischaemia	269
White matter lesions	273
Vascular zones, cerebral autoregulation and susceptibility to ischaemia	277
Maturation-related vulnerability of oligodendrocytes to injury in periventricular leukomalacia	278
Axonal injury in periventricular leukomalacia	282
Cerebral diffuse white matter gliosis	283
Long-term consequences of perinatal white matter damage	284
Combined grey and white matter lesions	285
Parasagittal cerebral injury	285
Neonatal 'stroke'	285
Porencephaly	289
Near-total asphyxia and multicystic encephalopathy	289
Cerebral haemorrhages	290
Intraventricular haemorrhage	290
Cerebellar haemorrhages	294
Intracerebral haemorrhage	294
Hypoglycaemia	295
Kernicterus	296
Infection	297
Neonatal meningitis	298
Meningitis in the infant	300
Fungal infections	300
TORCH infections	300
Birth trauma	304
Head and brain injuries	304
Nerve injury	305
Spinal cord and brain stem injury	305
Arthrogryposis multiplex congenita	306
Sudden infant death syndrome	306
Neuropathology of the stillborn	312
References	315

## Chapter 5: Malformations

*Brian N Harding and Andrew J Copp*

Introduction	335
Principles of nervous system development	335
Aetiology	336
Pathogenesis	348
A guide to interpreting the pathogenesis of malformations	356
Pathology of malformations	356
Neural tube defects: dysraphic disorders	356
Chiari malformations	363
Disorders of forebrain induction	368
Neuronal migration disorders	379
Encephaloclastic defects	403
Microcephaly	408
Environmental factors	410
Megalencephaly	412
Hemi-megalencephaly	412
Anomalies of the wall of the lateral ventricles	412
Third ventricular obliteration	413
Malformations of the cerebellum	413
Brain stem malformations	425
Malformations of the spinal cord	429
Syringobulbia	431
Vascular malformations	434
Arachnoid cysts	437
Phakomatosis	439
Hydrocephalus	444
Congenital disorders of the pituitary	448
Ectopic adenohypophysis	448
Pituitary aplasia/hypoplasia	448
Pituitary duplication or dystopia	448
Empty sella syndrome	449
Acknowledgements	449
References	449

## Chapter 6: Metabolic and neurodegenerative diseases of childhood

*Brian N Harding and Robert AH Surtees*

Introduction	481
Grey matter disorders	481
Alpers–Huttenlocher syndrome (progressive neuronal degeneration of childhood with liver disease)	481
Rett's syndrome	484
Infantile neuroaxonal dystrophy	485
Hallervorden–Spatz syndrome (pantothenate kinase-associated neurodegeneration or neurodegeneration with brain iron accumulation type I)	485
Leukoencephalopathy	488
Alexander's disease	488
Spongy leukodystrophy (Canavan or van Bogaert–Bertrand disease)	490
Pelizaeus–Merzbacher disease	491
Cockayne syndrome	491

Aicardi–Goutières leukoencephalopathy	493
Megalencephalic leukoencephalopathy with subcortical cysts	494
Vanishing white matter disease, or childhood ataxia with central hypomyelination syndrome	495
Pigmentary type of orthochromatic leukodystrophy	497
Inborn errors of intermediary metabolism	497
The hyperphenylalaninaemic syndromes	497
Non-ketotic hyperglycinaemia	498
The homocystinurias	499
Organic acid disorders	501
Urea cycle disorders	503
Congenital disorders of glycosylation	504
CDG-Ia (phosphomannomutase deficiency)	506
CDG-IIa ( <i>N</i> -acetylglucosaminyltransferase II deficiency)	506
References	506

## Chapter 7: Lysosomal diseases

*Kinuko Suzuki and Kunihiko Suzuki*

Introduction	515
Sphingolipidoses	515
Gangliosidoses	516
Niemann–Pick disease types A and B	528
Gaucher disease	530
Farber disease	533
Fabry disease	534
Metachromatic leukodystrophy and multiple sulphatase deficiency	535
Krabbe disease (globoid cell leukodystrophy)	539
Sphingolipid activator protein deficiencies	543
Mucopolysaccharidoses	544
Mucopolysaccharidosis I (Hurler and Scheie syndromes)	544
Mucopolysaccharidosis II (Hunter syndrome)	547
Mucopolysaccharidosis III (Sanfilippo disease)	551
Mucopolysaccharidosis IVA (Morquio A disease)	551
Mucopolysaccharidosis VI (Maroteaux–Lamy disease)	553
Mucopolysaccharidosis VII (Sly disease)	553
Mucopolysaccharidosis IX	554
Glycoprotein storage disorders	554
Sialidase (neuraminidase) deficiency (sialidosis, mucopolipidosis I)	554
$\alpha$ -Mannosidosis and $\beta$ -mannosidosis	555
Fucosidosis	557
Aspartylglucosaminuria (aspartylglucosaminuria)	558
Schindler disease ( $\alpha$ - <i>N</i> -acetylgalactosaminidase deficiency)	559
Galactosialidosis	561
Neuronal ceroid lipofuscinosis (Batten disease)	562
Congenital neuronal ceroid lipofuscinosis	563
Infantile neuronal ceroid lipofuscinosis (Haltia–Santavuori disease)	563
Late infantile neuronal ceroid lipofuscinosis (Jansky–Bielschowsky disease)	565
Juvenile neuronal ceroid lipofuscinosis (Spielmeyer–Vogt–Sjögren–Batten disease)	568

Adult neuronal ceroid lipofuscinosis (Kufs disease)	570
Other variant types of neuronal ceroid lipofuscinosis	570
Miscellaneous lysosomal disorders	571
Niemann–Pick disease, types C and D	571
I-cell disease and pseudo–Hurler polydystrophy (mucopolipidosis II and III)	576
Mucopolipidosis IV	577
Free sialic acid storage disorder (Salla disease and infantile sialic acid storage disease)	578
Sialuria	579
Cystinosis	580
Glycogen storage disease type II: acid $\alpha$ -glucosidase (acid maltase) deficiency (Pompe disease)	581
Lysosomal glycogen storage disease without $\alpha$ -glucosidase deficiency (Danon disease)	582
Acid lipase deficiency (Wolman disease, cholesteryl ester storage disease)	582
Acknowledgements	583
References	583

## Chapter 8: Mitochondrial diseases

*Patrick F Chinnery, Joanne Betts, Evelyn Jaros, Douglass Turnbull, Salvatore DiMauro and Robert H Perry*

Introduction	601
Mitochondrial biology: biochemistry and genetics	602
Clinical presentation of mitochondrial disorders	603
Chronic progressive external ophthalmoplegia (CPEO)	603
Kearns–Sayre syndrome	606
Pearson (bone marrow–pancreas) syndrome	607
Mitochondrial encephalopathy lactic acidosis and stroke-like episodes	607
Myoclonic epilepsy with ragged–red fibres	607
Leigh syndrome	608
Neuropathy, ataxia and retinitis pigmentosa	609
Leber hereditary optic neuropathy	609
Mitochondrial neuro-gastrointestinal encephalopathy syndrome (MNGIE)	609
Mitochondrial DNA depletion syndrome	609
Alpers–Huttenlocher syndrome	610
Mitochondrial myopathy	610
Investigation of suspected mitochondrial disease	610
Clinical studies	610
Systemic metabolic consequences of mitochondrial disease dysfunction	611
Muscle histopathology	612
Biochemical assessment of mitochondrial function	612
Genetic studies in mitochondrial disease	616
Mitochondrial encephalopathies: neuropathology	618
Kearns–Sayre syndrome	618
Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes	619
Myoclonic epilepsy with ragged–red fibres	621
Leigh syndrome	622
Leber hereditary optic neuropathy	625

Disorders with multiple mtDNA deletions, including mitochondrial neuro-gastrointestinal encephalomyopathy	630
Mitochondrial DNA depletion syndromes	632
Alpers–Huttenlocher syndrome	632
Mitochondrial peripheral neuropathies	632
Peripheral neuropathy due to mtDNA mutations	632
Peripheral neuropathy due to nDNA mutations	633
References	635

## Chapter 9: Peroxisomal diseases

*James M Powers*

Introduction	643
Peroxisomes	644
Peroxisomal disorders	644
General pathology and neuropathological overview of peroxisomal disorders	648
Leukodystrophies and other defects in myelination	649
Group I: disorders of peroxisome biogenesis	650
‘Classic’ Zellweger’s syndrome	650
Neuropathology of Zellweger’s syndrome	651
Neonatal adreno-leukodystrophy	654
Infantile Refsum’s or phytanic acid storage disease	655
Rhizomelic chondrodysplasia punctata, type I, classic	656
Group II: disorders with morphologically intact peroxisomes and a single protein deficiency	657
Pseudo-peroxisome biogenesis disorders	657
Adreno-leukodystrophy and adrenomyeloneuropathy	658
Refsum’s disease, classic or adult, and atypical Refsum’s disease	665
Group III: others	665
Specific treatment of peroxisomal disorders	666
Considerations on the cellular pathogenesis of peroxisomal disorders	666
Dedication	667
References	667

## Chapter 10: Nutritional deficiencies, metabolic disorders and toxins affecting the nervous system

*John Harris, Leila Chimelli, Jillian Kril and David Ray*

Introduction	675
Nutritional deficiencies	675
Introduction	675
Thiamine deficiency	676
Cobalamin deficiency	679
Niacin deficiency	680
Folate deficiency	681
Alcohol intoxication	681
Alcohol-related brain damage in the adult	681
Fetal alcohol syndrome	682
Central pontine myelinolysis and Marchiafava–Bignami disease	684
Disorders of the hypothalamic–pituitary axis	685

Introduction	685	Fate of the distal axotomy segment	743
Precocious puberty	686	Quantitation of axonal damage	743
Ectopic production of hypothalamic hormones	687	Traumatic axonal injury and microglial activation	743
Diabetes insipidus	689	Biomechanics of diffuse axonal injury	744
Hypothalamic hypogonadism	690	The neuronal somal (perikaryal) response to traumatic axonal injury	744
Hypothalamic dwarfism	691	Perisomatic axonal injury	745
Diencephalic syndrome	691	Synaptic changes in traumatic brain injury	745
Metabolic disorders of the pituitary	692	Microtubule-associated protein 2 as a marker of dendritic pathology	745
<b>Metabolic disorders</b>	692	Immediate-early gene activation in traumatic brain injury	745
Metabolic encephalopathies	692	Necrosis-apoptosis continuum in traumatic brain injury	746
Disorders of amino acid metabolism	694	Calcium in post-traumatic cell death	746
Urea cycle disorders	698	Apoptosis in experimental traumatic brain injury	746
Propionic acidaemia	700	Caspase-dependent apoptosis	747
Porphyrias	700	Caspase-independent apoptosis	747
<b>Neurotoxicology</b>	701	Free radical damage	747
Introduction	701	DNA damage in post-traumatic cell death	747
Neuronopathies	701	Cell death regulation by mitogen-activated protein kinases	748
Energy deficiency	703	Cerebral endothelial injury and traumatic brain injury	748
Excitotoxicity	705	Markers of endothelial damage in traumatic brain injury	749
Axonopathies	706	Endothelial injury and inflammatory cytokines	749
Myelinopathies	710	Blood-brain barrier and traumatic brain injury	749
General encephalopathies	711	Experimental blood-brain barrier dysfunction	749
Visual and auditory system damage	711	Diffuse vascular injury	750
Developmental neurotoxicity	712	Cerebral contusions	750
Food-related neurotoxicity	712	Types of contusion	751
Bites and stings	713	Contusion patterns and head impacts	753
Controversies and uncertainties	715	Clinicopathologic correlations	753
Acknowledgements	717	Quantitation of contusional injury	753
References	717	Microscopic changes in human contusions	753
		Resolution of contusions	754
<b>Chapter 11: Trauma</b>		Extradural (epidural) haematoma	754
<i>Peter Blumbergs, Peter Reilly and Robert Vink</i>		Subdural (intradural) haematoma	756
<b>Introduction</b>	733	Acute subdural haematoma	757
<b>Traumatic axonal injury</b>	737	Chronic subdural haematoma	758
Diffuse axonal injury (DAI)	738	Subdural fluid collections	759
Focal lesions in the corpus callosum	738	Traumatic subarachnoid haemorrhage	759
Focal lesions in the brain stem	739	Patterns of traumatic subarachnoid haemorrhage	759
Neuroimaging of focal lesions as a surrogate marker of diffuse axonal injury	739	Traumatic basal subarachnoid haemorrhage	759
Amyloid precursor protein and impaired axoplasmic transport	739	Massive generalized subarachnoid haemorrhage	760
Axonal amyloid precursor protein immunophenotypes and patterns	740	Sequelae of traumatic subarachnoid haemorrhage	760
Time-course and morphometry of amyloid precursor protein-immunopositive axonal injury	741	Traumatic intracerebral haemorrhage	760
Pathogenesis of traumatic axonal injury	741	Traumatic basal ganglia haematomas	761
Neurofilament proteins and traumatic axonal injury	742	Haem and iron metabolism following intracerebral haemorrhage	761
Neurofilament compaction type of axonal injury	742	Transferrin and iron removal following intracerebral haemorrhage	762
Neurofilament protein abnormalities of axons following diffuse brain injury in an inertial pig model	742	Traumatic intraventricular haemorrhage	762
Neurofilament compaction and impairment of axonal transport in different axons	742	Delayed deterioration after traumatic brain injury	763
Calpain activation and traumatic brain injury	743	Delayed traumatic intracerebral haematoma	763
<i>In vitro</i> traumatic axonal injury	743	Coagulopathy and traumatic brain injury	763
Microtubules and traumatic axonal injury	743	Carotid artery injuries	764
		Non-penetrating trauma of intracranial internal carotid arteries	764

Penetrating trauma of the extracranial carotid artery	764	Minimally conscious state	783
Non-penetrating trauma of vertebral arteries	764	Pathology of severely disabled patients following traumatic brain injury	783
Penetrating trauma of the vertebral arteries	765	Neuropathology of moderate disability post-trauma	784
Traumatic intracranial aneurysms	765	Apolipoprotein E and head injury	784
Clinical features of traumatic intracranial aneurysms	765	APOE genotype, traumatic brain injury and Alzheimer's disease	784
Brain swelling	765	Tau and traumatic brain injury	785
Cerebral oedema	765	A $\beta$ and tau in experimental traumatic brain injury	785
Congestive brain swelling	766	Brain injuries due to boxing	785
Brain swelling in head injury	766	Acute brain damage	785
Regulation of brain water and aquaporin 4	768	Chronic brain damage and boxing	786
Brain damage secondary to raised intracranial pressure	768	Post-traumatic seizures	786
Morphological patterns of raised intracranial pressure	768	Early seizures	786
Transtentorial hernia from a unilateral supratentorial mass lesion	768	Late seizures	786
Bilateral (central) transtentorial herniation	769	Glia and traumatic brain injury	787
Brain stem haemorrhages and raised intracranial pressure	769	Acute eosinophilic cytoplasmic swelling of glia	787
Tonsillar herniation	769	Reactive astrocytes and gliosis	788
Transfalcine herniation	770	Glutamate-mediated glial injury	788
Upward transtentorial herniation	770	Inflammation and traumatic brain injury	788
External ('fungus') herniation	770	Chemokines, adhesion molecules and leukocyte recruitment	788
Neuroimaging and clinical correlation of herniation syndromes	770	Interleukin 8	789
Neuropathological markers of raised intracranial pressure	771	Tumour necrosis factor $\alpha$	789
Amyloid precursor protein immunostaining and raised intracranial pressure	771	Interleukin 1 $\beta$	789
Primary and secondary brain stem haemorrhages	771	Interleukin 6	789
Ischaemic brain damage in traumatic brain injury	771	Interleukin 10 and transforming growth factor $\beta$	789
Pathological identification of ischaemic damage	772	The complement cascade in traumatic brain injury	789
Ischaemic damage and raised intracranial pressure	773	Microglial activation and macrophages	789
Global ischaemia	773	Regulation of central nervous system inflammation	790
Brain damage following cardiac arrest	775	Fracture of the skull	790
Brain damage in severe hypotension	775	Types of skull fracture	790
Brain damage restricted to specific arterial territories	775	Skull fracture and intracranial haemorrhage	791
Microvascular damage and traumatic brain injury	775	Biomechanics of traumatic brain injury	791
Hypoxaemia	776	Paediatric head injury	792
Vasospasm and ischaemic damage in traumatic brain injury	776	Traumatic brain injury in infants under 1 year of age	792
The ischaemic cell process (neuronal red cell change)	776	Traumatic brain injury in children over 1 year of age	793
Selective neuronal necrosis	776	Non-accidental head injury	793
Pathophysiology of ischaemic injury in traumatic brain injury	776	Clinical spectrum of non-accidental head injury	794
Diffusion-limited oxygen delivery	777	Clinicopathological features of the collapsed apnoeic baby	794
Mitochondrial failure, neuronal red cell change and traumatic brain injury	777	Clinical features of less severe non-accidental head injury	794
Brain stem lesions	777	Pathogenesis of non-accidental head injury	795
Primary traumatic brain stem haemorrhages	777	Falls and non-accidental head injury	795
Contusions and lacerations of the brain stem	777	Timing of non-accidental head injury	795
Pontomedullary disruption	778	Diffuse axonal injury and non-accidental head injury in infants	795
Secondary brain stem lesions	778	Rebleeding in chronic subdural haematoma and non-accidental head injury	795
Axonal injury and the brain stem	779	Retinal haemorrhages and non-accidental head injury	796
Concussive syndromes	779	The neuropathologist and non-accidental head injury	796
Memory and traumatic brain injury	780	Missile injuries due to firearms	796
Cholinergic basal forebrain and traumatic brain injury	781	Gunshot injuries due to low-velocity handguns and rifles	796
Long-term effects of traumatic brain injury	781	Clinical features	798
Post-traumatic vegetative state	782	Wounds from shotguns	799
Thalamic damage in post-traumatic vegetative state	783	Missile injuries and the dura	799
		Missile injuries and the skull	799

Long-term complications of gunshot wounds to the brain	799	Animal models of cortical malformations	836
Epilepsy and behavioural changes	799	Effects of seizures on the brain	837
Low-velocity penetrating injuries from missiles other than bullets	800	Mechanisms of neuronal injury and death	837
Gunshot wounds of the spinal cord	800	Effects of brief seizures	838
Stab wounds of the spinal cord	800	Influence of age and brain maturity on the effects of seizures	838
Stab wounds of the brain	801	Acquired (secondary) neuropathological changes as a consequence of seizures: post-mortem examination	838
Traumatic human spinal cord injury	801	Neuropathological features following status epilepticus	840
Introduction	801	Relationship between cerebral trauma and epilepsy	842
Primary and secondary spinal cord injury	801	Neurodegenerative diseases and epilepsy	843
Classification of spinal cord injury based on macroscopic pathology	801	Other forms of acquired symptomatic epilepsy	843
Acute spinal cord injury	802	Surgical pathology of epilepsy	843
Clinicopathological correlation of acute spinal cord injury	804	Hippocampal sclerosis	846
Axonal injury in human spinal cord injury	804	Malformations of cortical development and epilepsy	860
Demyelination and human spinal cord injury	804	Tumours and epilepsy	871
Inflammatory changes and spinal cord injury	805	Vascular malformations	872
Wallerian degeneration and spinal cord injury	805	Hamartomas and epilepsy	872
Mesenchymal scarring and spinal cord injury	805	Rasmussen's encephalitis	873
Cysts/cavities and post-traumatic syringomyelia	806	Myoclonic epilepsies	874
Schwannosis	806	Progressive myoclonic epilepsies	875
Mechanisms of spinal cord injury	807	References	877
Cervical spondylosis	807		
Spondylotic cervical myelopathy	807		
Nerve root compression (radiculopathy)	807		
Paediatric spinal cord injury	807		
Experimental spinal cord injury	808		
Experimental models	808		
Necrosis–apoptosis continuum in spinal cord injury	808		
Microglia and apoptosis after spinal cord injury	809		
Other mediators of cell death after spinal cord injury	809		
Inflammation and spinal cord injury	809		
Axonal injury and experimental spinal cord injury	810		
Demyelination and spinal cord injury	810		
Axonal regeneration: matrix proteins and inhibitory and trophic factors	810		
Astrocytic activation/glial fibrillary acidic protein upregulation	811		
Matrix metalloproteinases and spinal cord injury	811		
Gene expression patterns in spinal cord injury	811		
Cell replacement and spinal cord injury	811		
References	812		

## Chapter 12: Neuropathology of epilepsy

*Maria Thom, Sanjay Sisodiya and Imad Najm*

Introduction	833
Classification of epilepsies and clinical syndromes	833
Genetics and epilepsy	833
Clinical investigations and management in epilepsy	834
Animal models of epilepsy	836
Animal models of temporal lobe epilepsy and hippocampal sclerosis	836

## Chapter 13: Diseases of movement and system degenerations

*Paul G Ince, Brent Clark, Janice Holton, Tamas Revesz and Stephen B Wharton*

Introduction	889
Anatomy and function of basal ganglia	890
Trauma and movement disorders	893
Akinetic–rigid movement disorders	893
Parkinson's disease	893
Encephalitis lethargica and post-encephalitic parkinsonism	903
Drug- and toxin-related parkinsonism	904
Arteriosclerotic disease and parkinsonism	905
Dementia and parkinsonism	906
Guamanian and other forms of western Pacific parkinsonism	906
Progressive supranuclear palsy	907
Corticobasal degeneration	912
Multiple system atrophy	915
Neuronal intranuclear inclusion disease	918
Conditions characterized by abnormal stiffness	921
Hyperkinetic movement disorders	921
Chorea	921
Dystonia	928
Tic disorders	931
Degenerative ataxic disorders	932
Classification of degenerative ataxias	932
Autosomal recessive cerebellar ataxias	934
Autosomal dominant cerebellar ataxia	939
Mitochondrial encephalopathy	946
X-linked ataxias	946



Sporadic degenerative ataxia	947	Macroscopic appearance of Alzheimer's disease	1040
<b>Motor neuron disorders</b>	<b>947</b>	Histopathology of Alzheimer's disease	1041
Motor neuron disease (amyotrophic lateral sclerosis)	947	Molecular considerations and pathogenesis of Alzheimer's disease	1066
Post-polio syndrome	961	Genetic factors in Alzheimer's disease	1068
X-linked spinobulbar muscular atrophy (Kennedy's disease)	961	Biomarkers for Alzheimer's disease	1071
Spinal muscular atrophy	962	Transgenic mouse models of Alzheimer's disease	1071
Hereditary spastic paraparesis	968	<b>Disorders with Lewy bodies, including Parkinson's disease dementia</b>	<b>1073</b>
<b>Miscellaneous disorders affecting the deep grey nuclei</b>	<b>971</b>	Lewy bodies and Lewy neurites	1073
Thalamus	971	Lewy bodies in dementia syndromes	1074
Neuroaxonal dystrophy and related disorders	971	Dementia with Lewy bodies	1074
Calcification of the basal ganglia	974	Diagnostic terminology in disorders with dementia and Lewy bodies	1080
Striatal necrosis	975	Which lesions predict dementia in Lewy body disorders?	1081
Neuroleptic malignant syndrome	976	<b>Frontotemporal lobar degenerations, including tauopathies</b>	<b>1082</b>
Hereditary ferritinopathy (neuroferritinopathy)	977	Historical notes and evolution of concepts and terminology	1082
<b>Hepatocerebral syndromes and disorders of copper metabolism</b>	<b>978</b>	Clinical features of frontotemporal lobar degeneration	1084
Chronic acquired hepatocerebral degeneration	979	Pathological substrates of frontotemporal lobe degeneration	1085
Wilson's disease (hepatolenticular degeneration)	979	Genetics of frontotemporal lobe degeneration	1085
Menkes disease	980	Tau-associated disorders (tauopathies)	1086
Aceruloplasminaemia	980	Pick's disease	1087
<b>Abnormalities of central autonomic systems</b>	<b>980</b>	Progressive supranuclear palsy	1090
Central autonomic failure	981	Corticobasal degeneration	1091
Autopsy	981	Argyrophilic grain disease (dementia with grains)	1093
<b>Acknowledgements</b>	<b>981</b>	Tangle-predominant dementia	1093
<b>References</b>	<b>981</b>	Amyotrophic lateral sclerosis-parkinsonism-dementia complex	1095
		Frontotemporal dementia with parkinsonism linked to chromosome 17-tau	1095
		Frontotemporal lobar degeneration with TDP43 and ubiquitin inclusions	1100
		Neuronal intermediate filament inclusion disease	1103
		Dementia lacking distinctive histology	1104
		<b>Hippocampal sclerosis</b>	<b>1105</b>
		<b>Vascular dementia, including familial amyloid angiopathies</b>	<b>1105</b>
		Introduction	1105
		Epidemiological considerations	1107
		Which pathological lesions are important?	1107
		Mixed – vascular and Alzheimer's disease – dementia	1111
		Standardized approach to evaluation of vascular dementia	1112
		Vascular dementia and ethnic minorities	1113
		Familial disorders with vascular dementia, including familial amyloid angiopathy	1114
		<b>Normal-pressure hydrocephalus</b>	<b>1115</b>
		<b>Alcohol and dementia</b>	<b>1115</b>
		<b>Rare neurodegenerative disorders</b>	<b>1117</b>
		Thalamic dementia	1117
		Familial encephalopathy with neuroserpin inclusion bodies	1118
		Hereditodegenerative and metabolic causes of early-onset dementia	1118

## Chapter 14: Ageing and dementia

*James Lowe, Suzanne S Mirra, Bradley T Hyman and Dennis W Dickson*

<b>Introduction</b>	<b>1031</b>
<b>Concepts in the neuropathology of ageing and dementia</b>	<b>1031</b>
Accumulation of intracellular proteins as inclusion bodies: proteinopathies	1031
Accumulation of extracellular proteins as amyloid	1032
Neuronal loss and neurogenesis in ageing	1032
Neuroinflammation and cell stress	1032
<b>Ageing of the brain</b>	<b>1033</b>
Macroscopic changes, cortical atrophy and white matter changes	1033
Microscopic changes in ageing: neuronal, glial and vascular changes	1034
Age-related neuronal losses	1034
Age-related dendritic, axonal and synaptic changes	1035
Neuronal lipofuscin pigment	1035
Age-related glial changes	1036
Microscopic vascular pathology in the aged brain	1036
<b>Dementia</b>	<b>1036</b>
Definition of dementia	1036
Clinical diagnosis of dementia	1036
Epidemiology of dementia	1037
<b>Alzheimer's disease</b>	<b>1038</b>
Clinical features of Alzheimer's disease	1038
Epidemiology of Alzheimer's disease	1038

Diagnostic neuropathology considerations	1118	Experimental transmission to non-human primates	1205
Brain biopsy in dementia	1118	Transgenic models for the study of prion diseases	1206
An approach to pathological diagnosis	1119	<i>In vitro</i> models of prion disease	1207
Acknowledgements	1121	Experimental therapy for prion diseases	1207
References	1121	Prion decontamination	1208

## Chapter 15: Psychiatric diseases

*Margaret M Esiri and Tim J Crow*

Introduction	1153	Prion diseases in animals	1208
Categories and dimensions: the Kraepelinian dichotomy of psychosis and the significance of Schneiderian symptoms	1153	Scrapie	1209
Schizophrenic psychoses	1154	Bovine spongiform encephalopathy	1212
Epidemiology of schizophrenia	1155	Chronic wasting disease	1214
Are there environmental precipitants?	1157	Diagnosis of prion diseases	1215
Evidence for genetic factors	1158	Clinical diagnosis	1215
Natural history of schizophrenia	1159	Use of genetic techniques for the diagnosis of prion diseases	1217
Aetiological and pathophysiological hypotheses	1159	Neuropathology and differential diagnosis	1219
Language and the human brain	1161	Immunohistochemistry for PrP	1221
Brain structure in schizophrenia	1164	Western blot and other PrP <sup>Sc</sup> detection methods	1223
Schizophrenic symptoms in other diseases	1176	Sporadic Creutzfeldt–Jakob disease	1224
Dyskinesias in schizophrenia	1177	Definition and epidemiology	1224
Animal models of schizophrenia	1177	Clinical features and diagnostic criteria	1226
Interpretation of the brain changes in schizophrenia	1177	Clinical investigations and genetics	1227
Affective psychoses	1178	Neuropathology	1228
Brain structure	1178	Subtype 1: MM1/MV1	1229
Evidence from <i>in vivo</i> imaging	1178	Subtype 2: VV2	1229
Evidence from post-mortem studies	1180	Subtype 3: MV2	1230
Neurochemical changes in affective disorder	1180	Subtype 4: MM2	1231
Depression in Alzheimer's disease	1180	Subtype 5: VV1	1231
Other disorders	1180	Subtype 6: sporadic fatal insomnia (formerly known as the MM2 thalamic subtype)	1232
Autism	1180	PrP <sup>Sc</sup> detection and typing	1233
Dyslexia	1182	Familial prion diseases	1234
Attention deficit disorder	1183	Definition and epidemiology	1234
Schizotypal personality disorder	1183	Clinical and neuropathological features	1235
Conclusions	1184	Less common mutations associated with sporadic Creutzfeldt–Jakob disease-like phenotype	1237
References	1184	PrP <sup>Sc</sup> detection in familial Creutzfeldt–Jakob disease	1238
		Fatal familial insomnia	1238
		Gerstmann–Sträussler–Scheinker disease	1239
		Amyloid characterization in Gerstmann–Sträussler–Scheinker disease	1245
		PrP-cerebral amyloid angiopathy	1247
		Inherited prion disease with variable phenotype: the insertional mutations	1248
		Creutzfeldt–Jakob disease associated with deletions in the <i>PRNP</i> octapeptide repeat region: deletions of two 24-base pair repeats	1249
		Kuru	1249
		Definition and epidemiology	1249
		Clinical features and diagnostic criteria	1250
		Clinical investigations and genetics	1250
		Neuropathology	1250
		Iatrogenic Creutzfeldt–Jakob disease	1251
		Definition and epidemiology	1251
		Clinical features and diagnostic criteria	1252
		PrP <sup>Sc</sup> detection	1253
		Variant Creutzfeldt–Jakob disease	1253
		Definition and epidemiology	1253

## Volume 2

### Chapter 16: Prion diseases

*James W Ironside, Bernadino Ghetti, Mark W Head, Pedro Piccardo and Robert G Will*

Introduction	1197		
Background	1197		
Nature of the transmissible agent	1198		
History of prion diseases in humans	1199		
Prion biology	1199		
Definitions: introducing the prion hypothesis	1199		
PrP <sup>C</sup> and PrP <sup>Sc</sup>	1201		
Advances in understanding prion disease pathogenesis using animal models	1201		
Concept of prion agent strain	1204		
Neuropathology	1204		



The blood–brain barrier	1392	Metazoal infections	1473
Pathogenesis and pathophysiology of bacterial infection	1393	Nematode infections	1474
The immunocompromised patient	1395	Toxocariasis	1474
Pyogenic infections	1396	Strongyloidiasis	1475
Acute bacterial meningitis (purulent leptomeningitis)	1396	Eosinophilic meningoencephalitis	1475
Bacterial infections following neurosurgical procedures	1402	Angiostrongyliasis	1476
Brain abscess	1405	Gnathostomiasis	1476
Subdural abscess or empyema	1409	Trichinosis	1477
Epidural abscesses	1412	Filarial infections (filariasis)	1477
Vertebral osteomyelitis	1415	Onchocerciasis	1477
Discitis (spondylodiscitis)	1416	Loiasis	1478
Septic cavernous sinus thrombosis	1418	Other rare filarial infections of the CNS	1478
Intracranial mycotic (infective) aneurysm	1418	Other rare nematode infections	1478
Actinomycetal infections	1419	Trematode infections	1479
Mycobacterial infection	1419	Schistosomiasis	1479
Whipple's disease	1426	Paragonimiasis	1481
Actinomycosis	1427	Other rare trematode infections of the central nervous system	1482
Nocardiosis	1428	Cestode infections	1482
Spirochaetal infections	1428	Cysticercosis	1482
Neurosyphilis	1428	Coenurosis	1485
Borreliosis	1434	Hydatid disease	1486
Relapsing fever	1435	Sparganosis	1487
Leptospirosis	1435	Arthropod infections	1488
Brucellosis	1435	Myiasis	1488
Mycoplasma infections	1436	Oculomyiasis	1488
Rickettsial infections	1436	Fungal infections	1488
Sarcoidosis	1437	Aspergillosis	1489
Toxin-induced neurological disease	1438	Blastomycosis	1490
Diphtheria	1439	Candidiasis	1491
Infections caused by bacteria of the genus <i>Clostridium</i> : tetanus and botulism	1439	Coccidioidomycosis	1491
Shigellosis	1440	Cryptococcosis	1492
Miscellaneous infections	1440	Histoplasmosis	1494
References	1441	Chromomycoses	1496
		Paracoccidioidomycosis	1499
		Pneumocystosis	1499
		Penicilliosis	1499
		Sporotrichosis	1499
		Rhinosporidiosis	1500
		Zygomycosis (mucormycosis)	1500
		Other mycoses	1500
		References	1501

## Chapter 19: Parasitic and fungal infections

*Sebastian Lucas, Jeanne Bell and Leila Chimelli*

Introduction	1447
Routes of infection and pathogenesis	1447
Protozoal infections	1448
Falciparum malaria ( <i>Plasmodium falciparum</i> )	1448
Toxoplasmosis	1455
Sarcocystosis	1461
Trypanosomiasis	1462
Human African trypanosomiasis (African sleeping sickness)	1462
American trypanosomiasis (Chagas' disease)	1465
Amoebiasis	1468
Cerebral amoebiasis	1468
Primary amoebic meningoencephalitis	1468
Granulomatous amoebic encephalitis	1469
<i>Acanthamoeba</i> keratitis	1471
Encephalitis due to <i>Sappinia diploidea</i>	1471
Microsporidiosis	1472
Leishmaniasis	1473

## Chapter 20: Demyelinating diseases

*Raymond A Sobel and GR Wayne Moore*

Introduction	1513
Multiple sclerosis	1514
Introduction	1514
Clinical manifestations and diagnostic criteria	1516
Disease patterns and course	1518
Epidemiology	1518
Genetics	1520
Neuropathology: general considerations	1521
Marburg disease (acute multiple sclerosis)	1522
Pathology of early multiple sclerosis lesions	1523



Diabetic neuropathies	1687	Primary inherited muscle disorders	1763
Diabetes	1687	Muscular dystrophies	1763
Neuropathy with impaired glucose tolerance	1688	Duchenne and Becker muscular dystrophy	1763
Symmetrical sensorimotor polyneuropathy	1688	Limb-girdle dystrophies	1767
Asymmetrical diabetic neuropathies	1690	Congenital muscular dystrophies	1773
Diabetic autonomic neuropathy	1690	Emery-Dreifuss muscular dystrophy	1781
Pathogenetic mechanisms of diabetic neuropathy	1691	Bethlem myopathy	1784
Toxin-induced neuropathies	1693	Disorders associated with deletions or expansion of repeated sequences	1784
Axonopathies	1694	Congenital myopathies	1786
Myelinopathy	1695	Nemaline myopathy	1787
Toxins	1695	Central core disease	1788
Heavy metals	1696	Multicore disease	1790
Drugs	1697	Myotubular/centronuclear myopathy	1791
Metabolic neuropathies	1700	Myofibrillar myopathies	1792
Uraemia	1700	Inherited inclusion body myopathies	1794
Vitamin deficiencies	1700	Ion channel disorders	1795
Alcohol neuropathy	1701	Malignant hyperthermia	1796
Miscellaneous neuropathies	1701	Brody's disease	1797
Neuropathy related to systemic disease	1701	Myasthenic syndromes	1797
Paraneoplastic neuropathy	1703	Metabolic myopathies	1797
Acknowledgements	1705	Disorders of glycogen metabolism and glycolysis	1797
References	1705	Lysosomal glycogen storage with normal acid maltase (Danon's disease)	1801

## Chapter 22: Diseases of muscle

*Caroline A Sewry, Cecilia Jimenez-Mallebrera, Susan C Brown  
and Francesco Muntoni*

Introduction	1725
Clinical assessment of patients with neuromuscular disease	1726
Clinical assessment	1726
Investigations	1729
Normal muscle: structure and function	1731
Basic organization	1731
Muscle fibre basement membrane	1732
The myotendinous junction	1733
Proprioceptors in muscle	1733
Vasculature	1734
Sarcoplast	1734
Contractile apparatus	1734
Plasma membrane and internal membrane systems	1736
Muscle fibre cytoskeleton	1736
Nerves and innervation	1737
Neuromuscular junction	1737
Muscle fibre types	1738
Ultrastructural differences in fibre type	1740
Growth and development	1741
Neuromuscular transmission and muscle contraction	1742
General histological and histochemical abnormalities	1743
Application of immunohistochemistry in the diagnosis of neuromuscular disorders	1752
Developmental regulation of muscle proteins	1752
Primary protein defects in muscle detectable with immunohistochemistry	1754
Secondary defects	1755
Neurogenic disorders	1758
Spinal muscular atrophy	1760

Disorders of fatty acid metabolism	1802
Mitochondrial myopathies	1802
Other metabolic disorders	1803
Acquired disorders	1803
Inflammatory myopathies	1803
Connective tissue disorders	1806
Viral myositis	1806
Drug and toxic myopathies	1806
Endocrine myopathies	1806
References	1807

## Chapter 23: Tumours: introduction and neuroepithelial tumours

*David N Louis, Guido Reifenberger, Daniel J Brat and  
David W Ellison*

Introduction	1821
Epidemiology and aetiology	1821
Animal models of nervous system tumours	1827
Classification and grading	1831
Astrocytic tumours	1833
Overview and biology of diffuse astrocytic tumours	1833
Diffuse astrocytoma	1841
Anaplastic astrocytoma	1844
Glioblastoma	1846
Glioblastoma variants	1854
Pilocytic astrocytoma	1855
Pleomorphic xanthoastrocytoma	1860
Subependymal giant cell astrocytoma	1862
Oligodendroglial tumours	1865
Oligodendroglioma	1865
Anaplastic oligodendroglioma	1876

Oligoastrocytoma	1879	Melanocytic tumours and haemangioblastoma	2026
Anaplastic oligoastrocytoma	1882	Primary melanocytic lesions	2026
Other mixed gliomas	1884	Haemangioblastoma	2028
Ependymal tumours	1884	Bone tumours	2031
Ependymoma	1884	Bone-forming tumours	2032
Anaplastic ependymoma	1892	Cartilage tumours	2036
Myxopapillary ependymoma	1893	Giant cell tumour	2039
Subependymoma	1895	Ewing's tumour (Ewing's sarcoma)	2041
Choroid plexus tumours	1898	Aneurysmal bone cyst	2041
Glial tumours of uncertain origin	1902	Haemangioma	2043
Astroblastoma	1902	Haemangioendothelioma and angiosarcoma	2043
Chordoid glioma of the third ventricle	1905	Fibro-osseous lesions	2044
Gliomatosis cerebri	1907	Langerhans cell histiocytosis	2044
Neuronal and mixed neuronal-glial tumours	1910	Chordoma and related lesions	2045
Gangliocytoma	1910	Chordoma	2045
Ganglioglioma	1912	Benign lesions of notochord origin	2048
Desmoplastic infantile astrocytoma/desmoplastic infantile ganglioglioma	1917	Tumours of the peripheral nerves	2048
Central neurocytoma and other neurocytic neoplasms	1920	Schwannoma	2049
Cerebellar liponeurocytoma	1925	Variants of schwannoma	2051
Dysembryoplastic neuroepithelial tumour	1926	Neurofibroma	2053
Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease)	1929	Perineurioma	2055
Paraganglioma of the central nervous system	1933	Nerve sheath myxoma (myxoid neurothekeoma)	2056
Pineal parenchymal tumours	1936	Granular cell tumour	2056
Pineocytoma	1936	Malignant peripheral nerve sheath tumours	2057
Pineoblastoma	1939	Cysts and tumour-like conditions	2060
Pineal parenchymal tumour of intermediate differentiation	1941	Epidermoid cyst	2060
Papillary tumour of the pineal region	1942	Dermoid cyst	2061
Pineal cyst	1942	Colloid cyst	2063
Embryonal tumours	1943	Neurenteric (enterogenous) cysts	2064
Introduction	1943	Neuroepithelial cysts	2065
Medulloblastoma and primitive neuroectodermal tumours	1944	Ependymal (glioependymal) cysts	2065
Atypical teratoid/rhabdoid tumour	1957	Choroid plexus cysts	2065
Ependymblastoma	1959	Arachnoidal cyst	2066
Medulloepithelioma	1960	Glial cyst of the pineal gland	2066
Olfactory neuroblastoma (aesthesioneuroblastoma)	1961	Nasal glial heterotopia and nasal encephalocoeles	2067
References	1962	Inflammatory and histiocytic tumours	2067
<b>Chapter 24: Tumours: non-neuroepithelial tumours and secondary effects</b>		Lymphomas	2067
<i>David W Ellison, Arie Perry, Marc Rosenblum, Sylvia Asa, Robin Reid and David N Louis</i>		Primary CNS lymphoma	2067
		Other lymphoproliferative disorders in the CNS	2078
Tumours of meningeal cells	2002	Germ cell tumours	2081
Meningiomas	2002	Germinoma	2082
WHO grade I meningiomas	2006	Teratomas	2084
WHO grade II meningiomas	2010	Yolk sac tumours	2086
WHO grade III (malignant) meningiomas	2014	Embryonal carcinomas	2086
Non-meningothelial mesenchymal tumours of the meninges	2024	Choriocarcinomas	2086
Meningeal haemangiopericytoma/solitary fibrous tumour	2024	Mixed germ cell tumours	2086
Meningeal sarcomas	2025	Pituitary and suprasellar tumours	2088
		Introduction and methodology	2088
		Normal pituitary anatomy and cytology	2089
		Pituitary adenoma	2092
		Pituitary carcinoma	2106
		Craniopharyngioma	2107
		Gangliocytoma and ganglioneuroma	2109
		Granular cell tumour	2110
		Other primary neoplasms of the sellar region	2110
		Secondary neoplasms	2111

Tumour-like lesions	2112	Carney complex	2133
Hyperplasia	2112	Other hereditary brain tumour syndromes	2133
Inflammation	2112	Paraneoplastic syndromes	2133
Cysts	2116	General and pathogenic issues	2133
Metastatic tumours	2116	Paraneoplastic sensory neuropathy/encephalomyelitis	2135
General aspects of metastatic tumours	2116	Paraneoplastic cerebellar degeneration	2138
Meningeal carcinomatosis	2119	Paraneoplastic opsoclonus/myoclonus	2139
Hereditary tumour syndromes	2119	Therapy-associated neuropathology	2140
Neurofibromatosis	2121	Radiation necrosis and other forms of radiation injury	2140
Neurofibromatosis 1	2121	Therapy-induced leukoencephalopathies	
Neurofibromatosis 2	2124	and vasculopathies	2143
Schwannomatosis	2127	Therapy-induced secondary neoplasms	2144
Von Hippel–Lindau disease	2127	Genetic predispositions to therapeutic neurotoxicities	2145
Tuberous sclerosis	2128	Therapy-induced changes in the pituitary gland	2146
Li–Fraumeni syndrome	2130	References	2146
Cowden disease	2131		
Turcot syndrome	2132	Index	2183
Gorlin syndrome	2132		
Familial posterior fossa brain tumour of infancy syndrome	2133		